| Metric / Component | Grade | Score | Evidence & Rationale | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 62/100 | Micro-cap value trap with extreme growth outlier (EPS +157% YoY) but depressed P/E (4.63x). Hyper-growth flag offset by limited transparency and small float. Acceptable for tactical value, caution on liquidity. | 6–12 mo |
| SA Quality/Value Composite | C | 58/100 | P/E 4.63x vs. forward 6.86x suggests modest embedded discount; dividend yield 2.84% attractive for income, but sector cyclicality (insurance) warrants caution. Limited TTM revenue data constrains quality visibility. | 6–12 mo |
| Zacks Earnings Momentum | B | 76/100 | EPS growth YoY of +157.31% is exceptional; PEG ratio 0.029 is ultra-low, indicating massive upside relative to growth rate. EPS $6.51 on ~$30 stock price demonstrates significant per-share earnings power. Earnings date and forward guidance not disclosed—limits confirmation. | 1–3 mo |
| Institutional & Smart Money Flow | B– | 65/100 | $900M market cap + low avg volume (0.30M shares/day) = low institutional capacity. 52-week return +43.4% suggests prior smart money entry, but tight daily volume ($8.7M AUV at $30 price) creates execution friction. No insider/flow data in live feed—assessment cautious. | 6–12 mo |
| Growth Sustainability & Moat | C+ | 61/100 | Insurance sector, but 157% EPS growth is unsustainable long-term without market share gains or pricing power. Hyper-growth flag active; revenue growth only 1.35% YoY indicates earnings leverage from underwriting or expense control, not scale. Moat visibility limited by coverage gaps. | 6–12 mo |
| Valuation & Safety (Pre-Penalty) | B | 74/100 | P/E 4.63x is dirt cheap by absolute standards; 2.84% dividend yield + buyback potential. Beta 0.92 suggests lower systematic risk. 52-week range $16.83–$31.98: stock near recent highs but off lows = neutral signal. Forward P/E 6.86x adds modest lift. No earnings miss risk flagged. | 3–6 mo |
| Penalty Overlay | –12 | –12 pts | Micro-cap illiquidity (avg vol 0.30M/day) = execution risk on exit. Insurance sector cyclicality = earnings volatility. No earnings date or forward guidance disclosed = binary risk. "Weak balance" flag not active, but revenue stagnation (1.35% YoY) vs. EPS growth = leverage/accounting tailwind, not operational improvement. | 6–12 mo |
| CONFIDENCE SCORE | C+ | 63/100 | Live data complete on price, metrics, profile. Data gaps: earnings date, forward guidance, revenue TTM, insider flow. PEG ratio and dividend structure well-defined. Sector is mature; asset quality and claims trends opaque. Confidence is "guarded"—suitable for tactical, not strategic, positioning. | 6–12 mo |
| Volatility & Drawdown Risk | C | 57/100 | Beta 0.92 = below-market volatility on paper, but 52-week drawdown from $31.98 → $16.83 = –47% trough. Micro-cap + insurance = wider bid-ask, sudden repricing. Liquidity risk compounds beta illusion. Position sizing critical. | 3–12 mo |
| Crowding Risk Flag | MODERATE | 65/100 | 52-week return +43.4% + P/E 4.63x suggests retail/value hunter accumulation. However, avg volume 0.30M/day is thin—large crowding unlikely. Micro-cap thesis = contrarian, not consensus. Watchlist growth may accelerate if EPS confirmation released. | 3–6 mo |
Heritage Insurance Holdings operates in the Property & Casualty Insurance sector, a mature, cyclical industry with structural pricing discipline and underwriting discipline. As a micro-cap ($906M) within a sector dominated by mega-caps (Berkshire, Progressive, Allstate, $50B–$200B+ each), HRTG has limited brand reach but potentially higher ROE and niche underwriting focus (likely regional or specialty P&C).
Relative Valuation: Mega-cap P&C insurers typically trade 0.8–1.2x book value and 8–12x forward earnings. HRTG's 4.63x P/E is materially cheaper, suggesting either (a) hidden asset quality issues, (b) upcoming earnings cliff, or (c) temporary despair undervaluation. The 2.84% dividend yield is in-line with sector but underscores low growth expectations baked into consensus pricing. The explosive 157% EPS growth is highly atypical for insurance—likely driven by one-time releases (reserve revisions), catastrophe recoveries, or leverage expansion rather than organic underwriting improvement.
| Horizon | Base Case Scenario | Bull Case Catalyst | Bear Case Risk |
|---|---|---|---|
| 1–3 Months | Consolidation near $28–$32; EPS reconfirmation at next earnings call is critical. Dividend continued (2.84% yield = ~$0.85/sh annually). Small-cap rotation into value during rate volatility. | Q3 2026 earnings beat on underwriting margin or reserve release; analyst coverage expansion; institutional nibbling into low float. | Earnings miss or guidance cut (esp. if catastrophe spike, loss ratio deterioration, or reserve adequacy questions). Dividend cut = major sell signal. |
| 6–12 Months | Mean reversion: P/E re-rates toward 7–9x if EPS growth normalizes to 5–10% CAGR. Stock drifts to $32–$38 on organic growth + buyback. Liquidity slowly improves with retail awareness. | Strategic M&A (large insurer acquires HRTG at 1.2x BV premium); catastrophe-free underwriting year releases additional reserves; capital return (buyback) announced. | Insurance sector downturn (rising loss ratios, catastrophe cluster); rate hardening cycle reverses; HRTG forced to cut dividend or raise capital (dilution). Micro-cap liquidity crunch on macro shock. |
Core Thesis: HRTG's P/E of 4.63x + PEG of 0.029 represent extreme undervaluation if the 157% EPS growth is real and sustainable. However, insurance earnings volatility, opaque reserve dynamics, and missing forward guidance create binary risk. The 2.84% dividend is attractive for income but masks slow organic growth (1.35% revenue YoY). Micro-cap liquidity ($8.7M AUV) is a critical execution risk for any position >$500K notional.
Recommended Action:
- BUY (Tactical) — Limit to 0.5–1% of portfolio; target entry $27–$29 on weakness; set stop-loss at $24 (–20%); target exit $34–$38 (12–18 mo) or upon earnings confirmation failure.
- HOLD (if already owned) — Monitor Q3 2026 earnings release closely; expect volatility; dividend reinvestment + small scale-up on dips acceptable.
- AVOID (if capital-constrained or illiquidity-averse) — Better micro-cap value plays with clearer moats exist; HRTG demands active management.
Master Score: 62/100 (C+) — Hold-worthy valuation offset by execution risk; suitable for specialists, not general portfolios.
HRTG Stock Analysis & Forecast
Is HRTG a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
HRTG Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, HRTG shows balanced risk-reward characteristics.
Should You Buy HRTG Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in HRTG.